Related references
Note: Only part of the references are listed.Construction of 124I-trastuzumab for noninvasive PET imaging of HER2 expression: from patient-derived xenograft models to gastric cancer patients
Xiaoyi Guo et al.
GASTRIC CANCER (2020)
Development of 64Cu-NOTA-Trastuzumab for HER2 Targeting: A Radiopharmaceutical with Improved Pharmacokinetics for Human Studies
Sang-Keun Woo et al.
JOURNAL OF NUCLEAR MEDICINE (2019)
Functional Imaging of Human Epidermal Growth Factor Receptor 2-Positive Breast Cancers and a Note about NOTA
Joanne E. Mortimer et al.
JOURNAL OF NUCLEAR MEDICINE (2019)
Tumor Uptake of Cu-64-DOTA-Trastuzumab in Patients with Metastatic Breast Cancer
Joanne E. Mortimer et al.
JOURNAL OF NUCLEAR MEDICINE (2018)
Evolution of Cancer Pharmacological Treatments at the Turn of the Third Millennium
Luca Falzone et al.
FRONTIERS IN PHARMACOLOGY (2018)
Preclinical and clinical applications of specific molecular imaging for HER2-positive breast cancer
Wei Chen et al.
CANCER BIOLOGY & MEDICINE (2017)
89Zr-Trastuzumab PET/CT for Detection of Human Epidermal Growth Factor Receptor 2-Positive Metastases in Patients With Human Epidermal Growth Factor Receptor 2-Negative Primary Breast Cancer
Gary A. Ulaner et al.
CLINICAL NUCLEAR MEDICINE (2017)
64Cu-DOTA-trastuzumab PET imaging for HER2-specific primary lesions of breast cancer
S. Sasada et al.
ANNALS OF ONCOLOGY (2017)
[89Zr]Trastuzumab: Evaluation of Radiation Dosimetry, Safety, and Optimal Imaging Parameters in Women with HER2-Positive Breast Cancer
Richard Laforest et al.
MOLECULAR IMAGING AND BIOLOGY (2016)
HER2 expression status in diverse cancers: review of results from 37,992 patients
Min Yan et al.
CANCER AND METASTASIS REVIEWS (2015)
64Cu-DOTA-trastuzumab PET imaging and HER2 specificity of brain metastases in HER2-positive breast cancer patients
Hiroaki Kurihara et al.
EJNMMI RESEARCH (2015)
Functional Imaging of Human Epidermal Growth Factor Receptor 2-Positive Metastatic Breast Cancer Using Cu-64-DOTA-Trastuzumab PET
Joanne E. Mortimer et al.
JOURNAL OF NUCLEAR MEDICINE (2014)
111In-Trastuzumab Scintigraphy in HER2-Positive Metastatic Breast Cancer Patients Remains Feasible during Trastuzumab Treatment
Sietske B. M. Gaykema et al.
MOLECULAR IMAGING (2014)
64Cu-DOTA-Trastuzumab PET Imaging in Patients with HER2-Positive Breast Cancer
Kenji Tamura et al.
JOURNAL OF NUCLEAR MEDICINE (2013)
Copper-64 radiolabeling and biological evaluation of bifunctional chelators for radiopharmaceutical development
Ravindra A. De Silva et al.
NUCLEAR MEDICINE AND BIOLOGY (2012)
HER2 discordance between primary breast cancer and its paired metastasis: tumor biology or test artefact? Insights through meta-analysis
Nehmat Houssami et al.
BREAST CANCER RESEARCH AND TREATMENT (2011)
Imaging cancer using PET - the effect of the bifunctional chelator on the biodistribution of a Cu-64-labeled antibody
Jason L. J. Dearling et al.
NUCLEAR MEDICINE AND BIOLOGY (2011)
Share Paper
